Last reviewed · How we verify
TST001
At a glance
| Generic name | TST001 |
|---|---|
| Sponsor | Suzhou Transcenta Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
- Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma (PHASE3)
- A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
- TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer (PHASE2)
- Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TST001 CI brief — competitive landscape report
- TST001 updates RSS · CI watch RSS
- Suzhou Transcenta Therapeutics Co., Ltd. portfolio CI